Based on DESTINY-Breast06 Phase III trial results which showed Enhertu demonstrated superiority vs. chemotherapy with a median progression-free survival of more than one year
BRAFTOVI combination regimen is the first and only targeted therapy approvedby the U.S. FDA for treatment-naïve patients with metastatic colorectal cancer with a BRAF V600E mutation
EBITDA margins expand to 31.3%
Scored 85/100, 2.3x the industry average in Social and 73/100, 1.8x the industry average in Governance
The revenue from operations in Q3 FY25 is Rs. 8,358.6 crore, up 16% YoY
Expand the scope of the Production-Linked Incentive (PLI) scheme and increase its allocation to cover more pharmaceutical products and raw materials
The change is reflective of the company’s evolving vision aimed at further strengthening its global presence and a commitment to providing innovative solutions in the API and CDMO space
Datroway is the eighth new medicine of the 20 AstraZeneca has set out to deliver by 2030
Based on ECHO Phase III trial results which showed more than 16 months of progression-free survival improvement vs. chemoimmunotherapy alone
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Rexulti Tablets
Subscribe To Our Newsletter & Stay Updated
